Hemophilia B, also known as factor IX deficiency, is the second most common type of hemophilia. This podcast will discuss the limitations of current therapeutic options for Hemophilia B and explore the use of the new gene therapy, Hemgenix® (etranacogene dezaprarvovec), the most expensive drug in the world, from both a clinical and cost perspective.
SPEAKERS
Surabhi Palkimas, PharmD, MBA is currently in a leadership role in 340B contract pharmacy at University of Colorado
Hospital (UCH) and a is Clinical Assistant Professor at Skaggs School of Pharmacy and Pharmaceutical Sciences, Her research focuses on bleeding and clotting disorders, including heparin induced thrombocytopenia, venous thromboembolism, thrombotic thrombocytopenic purpura, hemophilia and von Willebrand disease with a focus on obese patients and use of direct oral anticoagulants in special patient populations, such as those with cancer, renal failure/transplant, heme malignancies, heparin induced thrombocytopenia and antiphospholipid syndrome.
Donna M. Lisi, PharmD, BS Pharmacy, BCPS, BCPP, BCACP, BCGP, BCMTMS is an Independent Consultant Clinical Pharmacist. Dr. Lisi completed her BS in Pharmacy and PharmD degrees from St. John’s University in New York and a post-doctoral fellowship in Geriatric Pharmacy at Montefiore Medical Center in the Bronx. She holds board certifications in Pharmacotherapy, Geriatric Pharmacy, Psychiatric Pharmacy, Ambulatory Care Pharmacy, and Medication Therapy Management. Dr. Lisi has worked in academia, long-term care, acute care, behavioral health, hospice, and medical communications.